Peter Maag, Kyverna Therapeutics CEO

Kyver­na Ther­a­peu­tics adds $60M to the bank as it pre­pares to show­case ear­ly CAR-T da­ta in lu­pus nephri­tis

Kyver­na Ther­a­peu­tics’ an­ti-CD19 CAR-T is draw­ing new in­vestors to lead a $60 mil­lion in­fu­sion, re­load­ing as it steers through ear­ly clin­i­cal tri­als in au­toim­mune dis­eases …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.